Literature DB >> 25921038

Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.

Claire M Modica1, Niels Bergsland2, Michael G Dwyer3, Deepa P Ramasamy4, Ellen Carl4, Robert Zivadinov5, Ralph Hb Benedict6.   

Abstract

BACKGROUND: Cognitive decline is characterized in multiple sclerosis (MS), but the rate and severity vary. The reserve hypothesis proposes that baseline neurological differences impact cognitive outcome in neurodegenerative disease.
OBJECTIVE: To elucidate how brain reserve and cognitive reserve influence subcortical gray matter (SCGM) atrophy and cognitive decline in MS over 3 years.
METHODS: Seventy-one MS patients and 23 normal controls underwent magnetic resonance imaging and cognitive assessment at baseline and 3-year follow-up. The influence of reserve on cognitive processing speed (CPS) and memory was examined.
RESULTS: SCGM volume and cognitive scores were lower in MS than normal controls (P⩽0.001). Accounting for baseline, comparison of follow-up means yielded a difference between groups in SCGM volume (P<0.001) but not cognition (NS). Cognitive reserve (P=0.005), but not brain reserve, contributed to CPS, with only low cognitive reserve MS subjects showing decline in CPS (P=0.029). SCGM change predicted CPS outcome in MS with low cognitive reserve (P=0.002) but not high cognitive reserve. There were no effects in the domain of memory.
CONCLUSIONS: SCGM atrophy occurs in normal controls, but significantly more so in MS. While CPS did not change in normal controls, low cognitive reserve was associated with CPS decline in MS. High cognitive reserve protect MS patients from cognitive decline related to SCGM atrophy.
© The Author(s), 2015.

Entities:  

Keywords:  MRI; Multiple sclerosis; cognitive impairment; cognitive reserve

Mesh:

Year:  2015        PMID: 25921038     DOI: 10.1177/1352458515579443

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  20 in total

Review 1.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

2.  White matter tract network disruption explains reduced conscientiousness in multiple sclerosis.

Authors:  Tom A Fuchs; Michael G Dwyer; Amy Kuceyeski; Sanjeevani Choudhery; Keith Carolus; Xian Li; Matthew Mallory; Bianca Weinstock-Guttman; Dejan Jakimovski; Deepa Ramasamy; Robert Zivadinov; Ralph H B Benedict
Journal:  Hum Brain Mapp       Date:  2018-05-08       Impact factor: 5.038

3.  Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.

Authors:  Gabriella Santangelo; Alvino Bisecco; Luigi Trojano; Rosaria Sacco; Mattia Siciliano; Alessandro d'Ambrosio; Marida Della Corte; Luigi Lavorgna; Simona Bonavita; Gioacchino Tedeschi; Antonio Gallo
Journal:  J Neurol       Date:  2018-05-26       Impact factor: 4.849

4.  Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.

Authors:  K B Casaletto; A M Staffaroni; A Wolf; B Appleby; D Brushaber; G Coppola; B Dickerson; K Domoto-Reilly; F M Elahi; J Fields; J C Fong; L Forsberg; N Ghoshal; N Graff-Radford; M Grossman; H W Heuer; G-Y Hsiung; E D Huey; D Irwin; K Kantarci; D Kaufer; D Kerwin; D Knopman; J Kornak; J H Kramer; I Litvan; I R Mackenzie; M Mendez; B Miller; R Rademakers; E M Ramos; K Rascovsky; E D Roberson; J A Syrjanen; M C Tartaglia; S Weintraub; B Boeve; A L Boxer; H Rosen; K Yaffe
Journal:  Alzheimers Dement       Date:  2020-01       Impact factor: 21.566

5.  Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Authors:  Yvonne Benešová; Aleš Tvaroh
Journal:  Ther Adv Neurol Disord       Date:  2016-10-21       Impact factor: 6.570

Review 6.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 7.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

8.  Is impaired cerebral vasoreactivity an early marker of cognitive decline in multiple sclerosis patients?

Authors:  Aude Metzger; Emmanuelle Le Bars; Jeremy Deverdun; François Molino; Bénédicte Maréchal; Marie-Christine Picot; Xavier Ayrignac; Clarisse Carra; Luc Bauchet; Alexandre Krainik; Pierre Labauge; Nicolas Menjot de Champfleur
Journal:  Eur Radiol       Date:  2017-10-12       Impact factor: 5.315

Review 9.  Measurement and maintenance of reserve in multiple sclerosis.

Authors:  Brian M Sandroff; Carolyn E Schwartz; John DeLuca
Journal:  J Neurol       Date:  2016-04-12       Impact factor: 4.849

10.  Longitudinal Stability of Cognition in Early-Phase Relapsing-Remitting Multiple Sclerosis: Does Cognitive Reserve Play a Role?

Authors:  Roxana M Barbu; Jason A Berard; Louise M Gresham; Lisa A S Walker
Journal:  Int J MS Care       Date:  2018 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.